QL2107 clinical trials
Also written QL2107.
A product of Pembrolizumab; its studies count on that page too.
How each study uses QL2107 has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QL2107 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 4 Sept 2014 · KEYTRUDA · BLA 125514 (FDA, Drugs@FDA; as pembrolizumab)
- European Union
- 17 Jul 2015 · Keytruda · EMEA/H/C/003820 (EMA; as pembrolizumab)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QL2107
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A biosimilar of Pembrolizumab
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test QL2107, phase 3 first.
- Dec 2026A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCPhase 3 · Qilu Pharmaceutical Co., Ltd.
- Dec 2026Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Phase 3 · Qilu Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses QL2107 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06754644Written as QL2107Report a problem
- A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy AdultsRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06173011Written as QL2107Report a problem
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07162883Written as QL2107Report a problem
Tested on its own · 2 — no other medicine in its arm
- A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy AdultsRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06173011Written as QL2107Report a problem
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07162883Written as QL2107Report a problem
Tested with established drugs · 1 — they are given beside it
Given beside what is tested · 7 — usual care or a partner of the new treatment
- A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07802821Written as QL2107Report a problem
- A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor PatientsRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT06911827In every armWritten as QL2107Report a problem
- QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07453394Written as QLS5132; QL1706; QL2107Report a problem
- A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07256782Written as QL2107Report a problem
- Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07151872Written as QL2107 InjectionReport a problem
- A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT06949761Report a problem
- Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT06942767In every armWritten as QL2107 InjectionReport a problem